Researchers identify PRC1 as key to establishing and maintaining ovarian reserve, providing insights into female reproductive health and lifespan. The study's findings may help explain premature ovarian failure and infertility in humans.
A new study published in the Journal of Clinical Oncology found that frequent aspirin use is linked with a 13% reduced risk of ovarian cancer in individuals with multiple risk factors. Aspirin benefitted most subgroups, including those with endometriosis and obesity.
Wistar scientists have identified a novel therapeutic approach that inhibits the gene KDM5A, which improves immune cell infiltration and attack on tumors. This approach has shown promising results in both in vitro and in vivo studies, including reduced tumor burden and improved survival rates in mice with ovarian cancer.
Researchers discover that malate dehydrogenase 2 (MDH2) is palmitoylated by ZDHHC18, increasing its activity and promoting mitochondrial respiration. This process sustains ovarian cancer cell proliferation both in vitro and in vivo.
Researchers from Bern and Geneva universities will receive $878,000 in funding to investigate mechanisms of resistance to PARPi inhibitors in BRCA-mutated ovarian cancer. The goal is to develop new targeted therapies to improve survival rates for patients with drug-resistant ovarian cancer.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
New research suggests vitamin D can effectively prevent ovarian cancer by restoring the body's natural defenses. The study found that vitamin D counteracts the process of peritoneal metastasis, which allows cancer cells to spread, and strengthens the barrier effect of mesothelial cells.
A new nanosensor platform uses machine learning to analyze spectral signatures of carbon nanotubes for early detection of ovarian cancer. The approach detects biomarkers and recognizes the cancer itself, offering a promising alternative to traditional methods.
Researchers at HKU have discovered a novel cellular and molecular interaction between cancer cells and tumour-associated macrophages that promote peritoneal metastasis of ovarian cancer. The study reveals that Wnt/b-catenin signalling upregulates the expression of metadherin, which communicates with macrophages through CEACAM1.
A recent study published in Endocrinology found that exposure to a scream sound may lead to diminished ovarian reserve and decreased fertility in female rats. The researchers discovered that the scream sound reduced estrogen and Anti-Mullerian hormone levels, as well as the number and quality of eggs, resulting in smaller litters.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
Researchers discovered that ovarian cancer tumors evade immune attack by redirecting tryptophan breakdown to the serotonin pathway, increasing NAD+ levels. Blocking this pathway with IDO1 inhibitors can be ineffective due to the adaptation of tumor microenvironments.
Researchers at University of Queensland have identified a genetic basis for the increased risk of epithelial ovarian cancer in women with endometriosis. The study found genes that could be targeted to treat both conditions, increasing understanding and treatment options.
Researchers at the University of Helsinki discovered that tumour cells in ovarian cancer hide from the body's immune system by interacting with specific gene mutations. Tumours with BRCA1/2 mutations are more effectively targeted by killer T-cells, leading to better patient outcomes.
A new symptom management approach, WRITE Symptoms, guides patients to reflect on their symptoms and develop strategies for addressing target symptoms. Both nurse-led and self-directed versions of the tool improved women's sense of control over their symptoms after eight weeks.
A clinical trial found that trametinib significantly slowed ovarian cancer progression by 13 months and increased treatment response by fourfold compared to standard care. The drug showed promise as a new standard of care for low-grade serous ovarian cancer, a common but difficult-to-treat form of the disease.
Researchers found trametinib to significantly improve progression-free survival and objective response rate in low-grade serous ovarian carcinoma. The median PFS was 13 months, while the ORR was 26%.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
Researchers have discovered that ovarian cancer begins with cancerous lesions in the fallopian tube linings of women with BRCA-1 mutations. The study's findings hold promise for predicting which women will develop ovarian cancer years or decades in advance, allowing for early detection and prevention strategies.
Researchers at Hokkaido University analyzed hundreds of women with ovarian granulosa cell tumors to improve understanding of the disease progression and response to therapy. They found that early-stage tumors rarely spread beyond the ovaries, and fertility-sparing surgery may be considered for younger patients.
Scientists used single-cell sequencing to analyze over 150,000 cells from 11 tumor samples, discovering novel mechanisms of tumor development and identifying potential targets for therapy. The findings may lead to personalized medicine and improved treatment options for gynecologic cancers.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers discovered that inhibiting a specific signaling pathway can prevent immunotherapy resistance in ovarian cancer, leading to improved tumor responses. This breakthrough has significant clinical implications and will inform a new clinical trial to test the efficacy of this approach.
A recent Ludwig Cancer Research study has identified a crucial cellular interaction that enhances the immune system's ability to destroy cancer cells. The interaction involves antigen-presenting cells (APCs) and T lymphocytes (TILs), which work together to boost and sustain T cell functionality. This discovery opens new avenues for tre...
Scientists at The Wistar Institute discovered that loss of ARID1A function enhances a cellular stress response pathway that promotes survival of cancer cells, making them sensitive to pharmacological inhibition. This finding points to a new therapeutic opportunity for ovarian clear cell carcinomas with ARID1A mutations.
Researchers found that BAK/MCL1 complexes can predict the sensitivity of paclitaxel and MCL1 inhibitors in ovarian cancer. The study suggests that this complex can be used to improve treatment outcomes for patients with ovarian cancer.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Researchers have discovered a new group of patients who are likely to benefit from PARP inhibitor therapy, which has shown unprecedented success in treating BRCA1/2 mutated cancers. The study identified tumours with epigenetic marks that silenced the RAD51C gene, making them sensitive to PARP inhibitors.
Researchers at Texas A&M University have developed an organ-on-a-chip that models the interaction between platelets and ovarian cancer tumors, revealing a crucial genetic signaling pathway. This breakthrough technology has potential applications in observing how cancer cells interact with blood vessels and testing novel treatments.
Researchers recreated ovarian follicle structures using mouse embryonic stem cells and successfully matured primordial germ cells into fully functional oocytes. The study provides a model system for studying later events of oogenesis and has implications for assisted reproductive technologies.
A world-first AI study will map genetic and physical risks of ovarian cancer based on UK Biobank data. The project aims to identify biomarkers for early detection and improve survival rates.
A new assessment tool has been found to predict ovarian damage in girls with cancer, helping doctors determine which patients should undergo fertility preservation. The Edinburgh selection criteria identify high-risk patients who are more likely to develop premature ovarian failure.
A recent study found that women previously infected with COVID-19 have similar ovarian reserve and fertility treatment outcomes compared to those without a history of the virus. The study monitored hormone levels in 46 patients undergoing IVF in Spain between May and June 2020, revealing no variation in anti-Mullerian hormone (AMH) lev...
Ovarian cancer is the most lethal gynaecological cancer with an absence of screening programmes, leading to late diagnosis and poor prognosis. Despite targeted therapies, personalized medicine remains a challenge due to inconsistent symptoms and resistance to chemotherapy.
A new study published in Proceedings of the National Academy of Sciences suggests that surgery should precede chemotherapy for certain patients with ovarian cancer. The research used a mathematical model to examine treatment outcomes and found that complete debulking surgery followed by chemotherapy provides better results. For patient...
A new radiopharmaceutical has been developed to treat ovarian cancer, dramatically limiting tumor growth and decreasing tumor mass. The treatment, which can be produced in just 25 minutes at low cost, shows promise as an efficient alternative to existing methods.
Researchers from NUS Cancer Science Institute have discovered a link between high levels of DNA repair protein RAD51 and platinum chemotherapy resistance in ovarian cancer patients. This finding could help identify patients who may require novel immunotherapy approaches to improve treatment outcomes.
A large-scale trial of annual screening for ovarian cancer found that neither method reduced deaths from the disease, contradicting expectations. Early detection strategies detected cancers earlier, but this did not translate into saving lives.
A study published in Nature Communications found that rucaparib is effective in treating ovarian cancers with inherited or somatic mutations in DNA repair genes. The drug targets the Achilles heel of cancers with defects in DNA repair, outperforming chemotherapy in early treatment stages.
A new study published in Diagnostics demonstrates that artesunate, a drug synthesized from Artemisia annua, kills ovarian cancer cells. The researchers found anticancer activity at achievable concentrations, supporting the clinical development of this strategy.
The UK Markey Cancer Center has launched a clinical trial to evaluate the anti-cancer activity of ArtemiLife coffee products in preventing ovarian cancer recurrence. Participants will drink coffee up to four times daily for five months after completing treatment, aiming to delay or eliminate cancer return.
A recent study found that end-of-life care for people with ovarian cancer has not improved significantly since 2007, with Black patients experiencing higher rates of emergency department visits and intensive treatment. Palliative care recommendations have been included in guidelines, but its adoption remains limited.
A new pilot study suggests that administering platelet-rich plasma and gonadotropins near the ovarian follicles can restore ovarian function in women during early menopause. The results show that 11 out of 12 participants resumed menstruation, with one achieving clinical pregnancy.
Golfers Against Cancer funds three CU Cancer Center researchers: Matthew Sikora studying genetic predispositions to ovarian cancer, Jamie Studts exploring lung cancer screening access, and Jenna Sopfe developing a standardized approach to sexual dysfunction in pediatric cancer survivors.
Researchers assessed tumor cell isolation and in vitro proliferation assays to predict chemotherapy response in ovarian cancer. In 12 of 14 cases, in vitro drug sensitivity correlated with clinical outcome.
A study by Queen Mary University researchers investigated how women at high risk of ovarian cancer make choices about possible preventive surgery. Women who have BRCA1 and BRCA2 genetic mutations have a higher lifetime risk of ovarian cancer, and may choose to undergo surgery to reduce their risk.
A new study from the University of Minnesota Medical School found that Pap test samples can detect proteins also present in ovarian cancer tumor tissues. This discovery suggests potential biomarker candidates for early detection of ovarian cancer, which currently has no early warning system.
Researchers found that antibodies produced by B cells predominantly have the IgA subtype, which inhibits RAS signaling, sensitizing tumor cells to T cell-mediated killing. This study provides insights into how immune components regulate ovarian cancer progression and offers new approaches for targeted immunotherapies.
Ovarian clear cell carcinoma (OCCC) remains a rare subtype with poor prognosis. Simvastatin efficiently controlled OCCC proliferation and migration, demonstrating potential as a candidate drug.
This study elucidates the molecular mechanism of 2-methoxyestradiol (2MeOE2) inducing apoptosis in ovarian tumors through PKCδ signaling. The findings suggest that 2MeOE2 activates PKCδ, leading to γH2Ax expression and apoptotic histone modifications, thereby driving apoptosis in ovarian cancer cells.
Researchers discovered that ovarian cancer cells undergo structural changes in their mitochondria to survive and proliferate in the peritoneal cavity. This adaptation enables aggressive cancerous cells to grow and spread, making it harder to detect and treat. Understanding these cellular adaptations could lead to new targeted therapies.
Mutations in the ARID1A gene increase glutamine metabolism in ovarian cancer cells, which can be blocked to target ARID1A-mutant tumors. Glutaminase inhibitors like CB-839 show promise as a standalone or combination therapy for clear cell ovarian carcinoma.
A retrospective study of patients with ovarian torsion found that older age, larger ovarian size, and gynecologic oncologist performance were linked to increased oophorectomy rates. The study suggests that surgeon ability to diagnose necrosis is poor, and patient race does not impact the likelihood of oophorectomy.
A comprehensive study of over 250,000 women found oral contraceptives significantly reduce the risk of ovarian and endometrial cancer, with benefits persisting even years after use ends. The findings contradict previous associations with increased breast cancer risk.
Women with frozen eggs and ovarian tissue had more children after breast cancer diagnosis compared to those without fertility preservation. The study highlights the importance of reproductive counseling for young breast cancer patients.
A new study published in JNCI: Journal of the National Cancer Institute indicates that receiving assisted reproductive technology does not increase the risk women have for developing ovarian cancer. While fertility treatments may slightly increase borderline ovarian tumor risk, this association appears to be due to underlying patient c...
Scientists have created a 3D tumour model for ovarian cancer, which can mimic the way tumour cells grow and respond to chemotherapy drugs. The new model has the potential to improve understanding and treatment of the disease.